Abstract: Osteogenic bone implant compositions that approximate the chemical composition of natural bone are provided. The organic component of these implant compositions is osteoinductive despite the presence of the inorganic component and, further, is present in an amount sufficient to maximize the regenerative capabilities of the implant without compromising its formability and mechanical strength. The composition may be an osteoinductive powder, including demineralized bone matrix (DBM) particles, a calcium phosphate powder, and, optionally, a biocompatible cohesiveness agent. The powder may be combined with a physiologically-acceptable fluid to produce a formable, osteoinductive paste that self-hardens to form a poorly crystalline apatitic (PCA) calcium phosphate having significant compressive strength. The bone implant materials retain their cohesiveness when introduced at an implant site and are remodeled into bone in vivo.
Type:
Grant
Filed:
April 12, 2004
Date of Patent:
July 17, 2012
Assignee:
Etex Corporation
Inventors:
Aron D. Rosenberg, Laurent D. Gilles de Pelichy, Daniel Egan, Aliassghar N. Tofighi, Dosuk D. Lee
Abstract: A method of preparation of a solid dispersion of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR with a BCS Class II drug or a BCS Class IV drug, whereby the method comprises: a) dissolving the polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) separately in a water/first alcohol mixture; and b) dissolving the BCS Class II drug or a BCS Class IV drug, in a mixture of a second alcohol with a non alcoholic organic solvent in which the compound has an high solubility; and c) mixing the both solutions to obtain a third solution with a total amount of solved solid of 1 to 15 g per 100 ml, and optionally having an acid, including inorganic acids including hydrohalic acids, e.g.
Abstract: The present invention provides a vaccine containing a Sendai virus vector encoding a virus protein of an immunodeficiency virus. By intranasally administering a Sendai virus encoding a virus protein of an immunodeficiency virus to a macaque monkey, the present inventors have succeeded in efficiently inducing protective immunity against an immunodeficiency virus. As a result of intranasal inoculation of vaccine, expression of an antigen protein mediated by Sendai virus vector was detected in intranasal mucous membrane and local lymph nodes and antigen-specific cellular immune response was induced at a significant level. No pathological symptom by vaccination was observed. After vaccination, exposure of simian immunodeficiency virus was performed and the effect was examined. As a result, the amount of virus in plasma significantly decreased, compared with that of the control animal. The present invention provides a promising vaccine as an AIDS vaccine.
Type:
Grant
Filed:
February 5, 2010
Date of Patent:
July 10, 2012
Assignees:
DNAVEC Research Inc., Japan as Represented by the Director General of National Institute of Infectious Disease
Abstract: The invention features delayed-setting calcium phosphate pastes which are useful for the preparation of delivery vehicles for biologically active agents, useful for the treatment of orthopedic conditions and can be stored for long periods without prematurely setting.
Type:
Grant
Filed:
April 14, 2005
Date of Patent:
July 10, 2012
Assignee:
ETEX Corporation
Inventors:
Dosuk D. Lee, Youngmi M. Lee, legal representative, Aron D. Rosenberg, Laurent D. Gilles De Pelichy, Manish Sutaria, Aliassghar N. Tofighi
Abstract: The invention features compositions for administration of an oxidatively transformed carotenoid or a component thereof and methods of promoting weight gain and feed conversion efficiency therewith.
Type:
Grant
Filed:
September 23, 2005
Date of Patent:
July 3, 2012
Assignee:
Chemaphor Inc.
Inventors:
Graham William Burton, Janusz Daroszewski
Abstract: The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
Abstract: The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.
Type:
Grant
Filed:
April 24, 2009
Date of Patent:
June 26, 2012
Assignee:
The Medicines Company (Leipzig) GmbH
Inventors:
Torsten Steinmetzer, Andrea Schweinitz, Joerg Stuerzebecher, Peter Steinmetzer, Anett Soeffing, Andreas Van De Locht, Silke Nicklisch, Claudia Reichelt, Friedrich-Alexander Ludwig, Alexander Schulze, Mohammed Daghisch, Jochen Heinicke
Abstract: The invention relates to plants, especially transgenic plants, plant parts and plant cells overproducing a secretory phospholipase A2 protein (e.g. sPLA2-a or sPLA2-b) and having an enhanced resistance against a wide range of abiotic (e.g., against osmotic stress) and biotic stress (e.g., bacterial, or fungal infections) conditions as well as inducing early flowering. The invention also comprises nucleic acid sequences encoding a secretory phospholipase A2 or functional isoforms thereof and the use of such sequences for rendering plants resistant against abiotic and biotic stress conditions. The invention is useful for mitigating crop damages by a wide variety of pathogen infections and stress conditions and for accelerating flowering time.
Type:
Grant
Filed:
February 15, 2008
Date of Patent:
June 19, 2012
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Inventors:
Stephen Beungtae Ryu, Hyoung-Yool Lee, In-Whan Hwang, P. Palta Jiwan
Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
Type:
Grant
Filed:
January 26, 2011
Date of Patent:
June 19, 2012
Assignee:
Eisai R&D Management Co., Ltd.
Inventors:
Atsushi Endo, Charles E. Chase, Francis G. Fang
Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.
Abstract: The field of the invention relates to the use of carbohydrate binding compounds as a medicine, their use to treat or prevent viral infections, their use to manufacture a medicine to treat or prevent viral infections and their use in a vaccination strategy. The present invention relates to the use of said compounds to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses having glycosilated envelop proteins such as Retroviridae (i.e. Lentivirinae), like HIV (human immunodeficiency virus), Flaviviridae, like HCV (hepatitis C virus), Hepadnaviridae, like HBV (hepatitis B virus), Coronaviridae, like SARS corona virus, and Orthomyxoviridae, like influenza A, B or C.
Type:
Grant
Filed:
September 21, 2006
Date of Patent:
June 5, 2012
Assignees:
K.U.Leuven Research & Development, Technische Universität Carolo Wilhelmina Zu Braunschweig
Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.
Type:
Grant
Filed:
April 7, 2005
Date of Patent:
June 5, 2012
Assignee:
Exiqon A/S
Inventors:
Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
Abstract: Disclosed are devices and methods for detecting, preventing, and/or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns.
Type:
Grant
Filed:
October 17, 2005
Date of Patent:
May 29, 2012
Assignees:
Louisiana Tech University Foundation, Inc., Board of Supervisors of Louisiana State University
Inventors:
Walter G. Besio, Mohammed Fasiuddin, Ravish Patwardhan
Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
May 29, 2012
Assignee:
Exiqon A/S
Inventors:
Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
Abstract: The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.
Type:
Grant
Filed:
October 8, 2007
Date of Patent:
May 29, 2012
Assignee:
Caregen Co., Ltd.
Inventors:
Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Sang Su Song
Abstract: The present invention provides a method for configuring a pattern recognizer using versatile, readily available data, comprehensive protein data, and comprehensive chemical data, as well as a method for predicting an unknown interaction of a pair by using the pattern recognizer-configuring method. An interaction such as the coupling between a protein and a chemical is used as an index; at least one of four parameters is vectorized; a vector containing elements of the vector derived from each protein and elements of the vector derived from each chemical paired with the protein is created; and a support vector machine (SVM) is applied to this vector and trained to learn them, where the pattern recognizer is configured so as to discriminate between a class to which the first pair belong and a class to which the second pair belong.
Abstract: The invention features an electrical connection apparatus capable of operatively attaching to an electrical appliance or electrical socket. The apparatus also includes at least two electrical connections which can communicate with each other to allow the flow of electrical charge therebetween. The apparatus can also be arranged to allow relative movement of the at least first and/or second electrical connection between a first position, wherein electrical charge can flow therebetween, and a second position, wherein the flow of electrical charge is prevented. The relative movement can take place over a pre-determined time period following actuation to provide a timing mechanism for the apparatus.
Abstract: The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.
Abstract: The present invention features a novel combination therapy useful in the treatment of autoimmune disease that increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system.